ReviewTherapeutic advances in hematology2013
Treatment and management of graft-versus-host disease: improving response and survival.
Review in Therapeutic advances in hematology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07576699 (CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease), which is not on this map. Cited by 107 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
CK0802 for Treatment of Steroid Refractory Graft vs. Host Disease (GVHD)
Who cites it
107 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis.Bone marrow transplantation · 2024Pooled it
- The risk of malignancies in patients receiving hematopoietic stem cell transplantation: a systematic review and meta-analysis.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2020Pooled it
- Mesenchymal stromal cells for the prophylaxis and treatment of graft-versus-host disease-a meta-analysis.Stem cell research & therapy · 2020Pooled it
- Novel highly selective ROCK2 inhibitor (TDI01) for the treatment of chronic graft-versus-host disease: a multicenter, open-label phase Ib/II study.Signal transduction and targeted therapy · 2026Trial
- Impact of concomitant azoles on ruxolitinib treatment in patients with GVHD: post hoc analyses of REACH2 and REACH3.Blood advances · 2025Trial
- "They knew the same struggles": perceptions of a group coping skills intervention in patients with chronic graft-versus-host disease.Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer · 2025Trial
- Pharmacokinetics, Relative Bioavailability, and Safety of the SHR0302 Oral Solution and Tablets: A Single-Center, Randomized, Open-Label, Crossover (Two-Formulation, Two-Period) Phase I Trial in Healthy Chinese Volunteers.Drug design, development and therapy · 2025Trial
- Vedolizumab for the prevention of intestinal acute GVHD after allogeneic hematopoietic stem cell transplantation: a randomized phase 3 trial.Nature medicine · 2024Trial
- Trial
- Group Coping Intervention in Patients With Chronic Graft-Versus-Host Disease: A Pilot Randomized Clinical Trial.Journal of the National Comprehensive Cancer Network : JNCCN · 2024Trial
- Trial
- Ibrutinib for First-Line Treatment of Chronic Graft-Versus-Host Disease: Results From the Randomized Phase III iNTEGRATE Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2023Trial
- Trial
- A biomarker signature to predict complete response to itacitinib and corticosteroids in acute graft-versus-host disease.British journal of haematology · 2022Trial
- Fludarabine and intravenous busulfan conditioning with post-transplantation cyclophosphamide for allogeneic peripheral stem cell transplantation for adult patients with lymphoid malignancies: a prospective single-arm phase II study.Frontiers of medicine · 2021Trial
- A phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host disease.Blood advances · 2020Trial
- Acute Graft-vs.-Host Disease-Associated Endothelial ActivationFrontiers in immunology · 2019Trial
- Extracorporeal photopheresis with TC-V in Japanese patients with steroid-resistant chronic graft-versus-host disease.International journal of hematology · 2018Trial
- Mesenchymal stromal cell infusion to treat steroid-refractory acute GvHD III/IV after hematopoietic stem cell transplantation.Bone marrow transplantation · 2017Trial
- The real-world safety of ruxolitinib in graft-versus-host disease treatment: a pharmacovigilance study based on the FDA adverse event reporting system.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
47 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Graft-versus-host disease (GVHD) is a significant cause of morbidity and mortality following allogenic haematopoietic stem-cell transplantation and thus the focus of much ongoing research. Despite considerable advances in our understanding of the pathophysiology, diagnosis and predisposing factors for both acute and chronic forms of the disease, a standardised therapeutic strategy is still lacking. There is good evidence for initial treatment of both acute and chronic forms of the disease with corticosteroid therapy. However, the most effective approach to steroid-refractory disease remains controversial, with current practice based mainly on smaller studies and varying considerably between local institutions. Timely diagnosis, multidisciplinary working and good supportive care, including infection prophylaxis, are clearly important in optimizing response and survival in such patients. It is hoped that in the future systematic research strategies and the identification of novel therapeutic targets may improve outcome further. The following review aims to outline some of the existing options for the treatment and management of acute and chronic GVHD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.